$21.41
Insights on Acadia Pharmaceuticals Inc.
Revenue is up for the last 3 quarters, 118.46M → 211.69M (in $), with an average increase of 25.1% per quarter
Netprofit is down for the last 2 quarters, 1.11M → -65.17M (in $), with an average decrease of 5950.6% per quarter
In the last 1 year, Seagen, Inc. has given 83.0% return, outperforming this stock by 33.4%
In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 79.3%
0.98%
Downside
Day's Volatility :6.03%
Upside
5.1%
32.51%
Downside
52 Weeks Volatility :57.49%
Upside
37.01%
Period | Acadia Pharmaceuticals Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -17.78% | 0.3% | 0.0% |
6 Months | -7.09% | 1.7% | 0.0% |
1 Year | 49.6% | -4.0% | -2.4% |
3 Years | -58.24% | 17.2% | -6.5% |
Market Capitalization | 3.7B |
Book Value | $2.21 |
Dividend Share | 0.0 |
Dividend Yield | 5.43% |
Earnings Per Share (EPS) | -0.91 |
PEG Ratio | -0.42 |
Wall Street Target Price | 32.75 |
Profit Margin | -23.55% |
Operating Margin TTM | -27.29% |
Return On Assets TTM | -15.63% |
Return On Equity TTM | -37.78% |
Revenue TTM | 631.9M |
Revenue Per Share TTM | 3.87 |
Quarterly Revenue Growth YOY | 62.0% |
Gross Profit TTM | 145.5M |
EBITDA | -150.0M |
Diluted Eps TTM | -0.91 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.34 |
EPS Estimate Next Year | 0.91 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | 0.24 |
What analysts predicted
Upside of 52.97%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 124.9M | ↑ 620.68% |
Net Income | -289.4M | ↑ 6.64% |
Net Profit Margin | -231.71% | ↑ 1334.23% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 223.8M | ↑ 79.19% |
Net Income | -245.2M | ↓ 15.28% |
Net Profit Margin | -109.56% | ↑ 122.15% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 339.1M | ↑ 51.5% |
Net Income | -235.3M | ↓ 4.05% |
Net Profit Margin | -69.38% | ↑ 40.18% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 441.8M | ↑ 30.28% |
Net Income | -281.6M | ↑ 19.69% |
Net Profit Margin | -63.74% | ↑ 5.64% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 484.1M | ↑ 9.6% |
Net Income | -167.9M | ↓ 40.38% |
Net Profit Margin | -34.67% | ↑ 29.07% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 517.2M | ↑ 6.83% |
Net Income | -216.0M | ↑ 28.66% |
Net Profit Margin | -41.76% | ↓ 7.09% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 134.6M | ↑ 16.54% |
Net Income | -34.0M | ↓ 69.92% |
Net Profit Margin | -25.28% | ↑ 72.63% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 130.7M | ↓ 2.86% |
Net Income | -27.2M | ↓ 20.08% |
Net Profit Margin | -20.8% | ↑ 4.48% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 136.5M | ↑ 4.42% |
Net Income | -41.7M | ↑ 53.5% |
Net Profit Margin | -30.57% | ↓ 9.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 118.5M | ↓ 13.21% |
Net Income | -43.0M | ↑ 3.11% |
Net Profit Margin | -36.32% | ↓ 5.75% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 165.2M | ↑ 39.48% |
Net Income | 1.1M | ↓ 102.59% |
Net Profit Margin | 0.67% | ↑ 36.99% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 211.7M | ↑ 28.12% |
Net Income | -65.2M | ↓ 5950.63% |
Net Profit Margin | -30.79% | ↓ 31.46% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 384.5M | ↓ 31.48% |
Total Liabilities | 49.2M | ↑ 15.16% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 540.2M | ↑ 40.49% |
Total Liabilities | 61.1M | ↑ 24.18% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 783.2M | ↑ 44.98% |
Total Liabilities | 84.0M | ↑ 37.51% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 782.6M | ↓ 0.07% |
Total Liabilities | 155.6M | ↑ 85.14% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 700.1M | ↓ 10.54% |
Total Liabilities | 159.2M | ↑ 2.33% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 587.8M | ↓ 16.04% |
Total Liabilities | 187.4M | ↑ 17.69% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 612.8M | ↓ 1.84% |
Total Liabilities | 177.9M | ↓ 0.86% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 602.5M | ↓ 1.68% |
Total Liabilities | 176.8M | ↓ 0.63% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 587.8M | ↓ 2.44% |
Total Liabilities | 187.4M | ↑ 5.99% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 655.3M | ↑ 11.48% |
Total Liabilities | 281.0M | ↑ 49.97% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 642.8M | ↓ 1.91% |
Total Liabilities | 247.0M | ↓ 12.12% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 632.5M | ↓ 1.59% |
Total Liabilities | 270.4M | ↑ 9.47% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -217.9M | ↑ 3.54% |
Investing Cash Flow | 92.5M | ↓ 135.31% |
Financing Cash Flow | 31.2M | ↓ 94.16% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -167.5M | ↓ 23.13% |
Investing Cash Flow | -71.5M | ↓ 177.31% |
Financing Cash Flow | 306.6M | ↑ 883.22% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -151.1M | ↓ 9.76% |
Investing Cash Flow | -165.8M | ↑ 131.97% |
Financing Cash Flow | 371.8M | ↑ 21.26% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -136.2M | ↓ 9.9% |
Investing Cash Flow | 192.5M | ↓ 216.08% |
Financing Cash Flow | 81.0M | ↓ 78.22% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -125.7M | ↓ 7.72% |
Investing Cash Flow | -71.1M | ↓ 136.93% |
Financing Cash Flow | 18.2M | ↓ 77.58% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -114.0M | ↓ 9.25% |
Investing Cash Flow | 73.2M | ↓ 203.01% |
Financing Cash Flow | 8.2M | ↓ 54.86% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.1M | ↓ 82.8% |
Investing Cash Flow | -55.8M | ↓ 142.48% |
Financing Cash Flow | 3.8M | ↑ 55.29% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -727.0K | ↓ 94.46% |
Investing Cash Flow | 15.4M | ↓ 127.67% |
Financing Cash Flow | 287.0K | ↓ 92.51% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -23.9M | ↑ 3181.16% |
Investing Cash Flow | -17.7M | ↓ 214.94% |
Financing Cash Flow | 1.6M | ↑ 462.37% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.9M | ↓ 24.82% |
Investing Cash Flow | 192.5M | ↓ 1184.73% |
Financing Cash Flow | 1.5M | ↓ 9.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.2M | ↓ 145.73% |
Investing Cash Flow | -194.3M | ↓ 200.92% |
Financing Cash Flow | 5.5M | ↑ 273.67% |
Sell
Neutral
Buy
Acadia Pharmaceuticals Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Acadia Pharmaceuticals Inc. | -7.05% | -7.09% | 49.6% | -58.24% | 17.87% |
![]() Moderna, Inc. | 8.62% | -38.31% | -54.89% | -50.93% | 320.86% |
![]() Regeneron Pharmaceuticals, Inc. | -1.38% | 9.73% | 9.82% | 65.7% | 115.07% |
![]() Novo Nordisk A/s | -1.43% | 23.95% | 58.41% | 192.13% | 336.59% |
![]() Seagen, Inc. | 0.74% | 10.42% | 83.05% | 20.41% | 247.89% |
![]() Vertex Pharmaceuticals Incorporated | -8.19% | 7.19% | 13.58% | 55.97% | 97.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Acadia Pharmaceuticals Inc. | NA | NA | -0.42 | -0.34 | -0.38 | -0.16 | 0.05 | 2.21 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Acadia Pharmaceuticals Inc. | Buy | $3.7B | 17.87% | NA | -23.55% |
![]() Moderna, Inc. | Buy | $30.4B | 320.86% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 115.07% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 336.59% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 247.89% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 97.18% | 26.38 | 35.94% |
Baker Bros Advisors LP
Vanguard Group Inc
BlackRock Inc
RTW INVESTMENTS, LLC
EcoR1 Capital, LLC
FMR Inc
Acadia Pharmaceuticals Inc.’s price-to-earnings ratio stands at None
Read Moreacadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
Organization | Acadia Pharmaceuticals Inc. |
Employees | 580 |
CEO | Mr. Stephen R. Davis J.D. |
Industry | Health Technology |